Author By medregenPosted on
A multi-center international trial studying the immunoregulatory and regenerative potential of MRG-001 in severe and critically ill COVID-19 patients has been initiated by MedRegen.
Author By medregenPosted on
MedRegen has successfully completed the phase I study in healthy volunteers. MRG-001 has demonstrated to be safe across all dosages and effective in the mobilization of stem cells.
Author By medregenPosted on
MedRegen has teamed up with ICON plc to initiate its first clinical trial in healthy subjects to evaluate the safety, pharmacokinetics and pharmacodynamics of MRG-001 in San Antonio, Texas.
Author By medregenPosted on
MedRegen is proud to announce that the FDA has approved the IND applications for a combined phase 1/2 clinical trial with MRG-001 for the treatment of COVID-19 disease.